STOCK TITAN

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Phathom Pharmaceuticals, Inc. will report its first quarter 2024 financial results and provide a business update on Thursday, May 9, 2024. The company, listed on Nasdaq as PHAT, focuses on developing and commercializing novel treatments for gastrointestinal diseases. A live webcast will be hosted at 8:30 am ET on the mentioned date, with access to the presentation available on the company's website.

Positive
Negative
  • Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET

FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, May 9, 2024, to report its first quarter 2024 financial results and provide an update on business progress.

A live webcast and additional information about the presentation can be accessed on the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of Erosive GERD and relief of related heartburn in adults, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2024 Phathom Pharmaceuticals. All rights reserved.


FAQ

When will Phathom Pharmaceuticals report its first quarter 2024 financial results?

Phathom Pharmaceuticals will report its first quarter 2024 financial results on Thursday, May 9, 2024.

What is the stock symbol of Phathom Pharmaceuticals?

The stock symbol of Phathom Pharmaceuticals is PHAT.

What is the focus of Phathom Pharmaceuticals' business?

Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases.

Where can I access the live webcast of Phathom Pharmaceuticals' financial results report?

The live webcast of Phathom Pharmaceuticals' financial results report can be accessed on the News & Events section of the company's website at https://investors.phathompharma.com/news-events/events-and-presentations.

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

PHAT Rankings

PHAT Latest News

PHAT Stock Data

625.74M
42.90M
8.81%
87.86%
18.21%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
FLORHAM PARK

About PHAT

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.